Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811365 · ClinicalTrials.gov registry record
(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation
A clinical trial of KIT D816V Mutation and Systemic Mast Cell Activation, sponsored by Blueprint Medicines Corporation.
- Completed
- Registry status
- 379
- Enrollment target
- 20
- Study locations
NCT04811365: Completed study of KIT D816V Mutation and Systemic Mast Cell Activation, sponsored by Blueprint Medicines Corporation.
NCT04811365 is a study of KIT D816V Mutation and Systemic Mast Cell Activation that has completed, run by Blueprint Medicines Corporation. The registered enrollment target is 379 participants. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04811365, a study of KIT D816V Mutation and Systemic Mast Cell Activation, has completed, sponsored by Blueprint Medicines Corporation.
- COMPLETED
- Registry status
- 379 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center screening study with the primary objective to determine the prevalence of KIT D816V mutation in peripheral blood in patients with evidence of systemic mast cell activation (MCA).
Conditions Studied
Interventions
- OTHER Screening
Study Locations (20)
Other
- Antwerp University Hospital UZA - Edegem
- Pitié-Salpêtrière Hospital - Paris
- CHU Toulouse - Toulouse
- Charite Universitatsmedizin Berlin - Berlin
- Medizinische Hochschule Hannover, Dept. of Dermatology and Allergy - Hanover
- Klinik fuer Dermatologie und Allergologie - München
- AOU San Giovanni di Dio e Ruggi d'Aragona University of Salerno - Salerno
- Azienda Ospedaliera Universitaria Integrata Verona - Verona
- Hospital Virgen del Valle - Toledo
- University of Basel - Basel
New York
- Roswell Park Cancer Center - Buffalo
- Albert P. Hirdt D.O. P.C. - New Paltz
- Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center HICCC - New York
Alabama
- Clinical Research Center of Alabama - Birmingham
California
- Scripps Clinic Carmel Valley - San Diego
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Duke University: Duke Allergy Asthma Airway Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 379 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2023-03-31 |
What the finished NCT04811365 record still lists
NCT04811365 is an observational study that tracks outcomes without assigning an intervention. The registered 379 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with KIT D816V Mutation appearing as the primary indexed condition, and to 1 intervention - of which Screening is the first listed.
NCT04811365 names 20 study sites across 9 states, led by Other, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT04811365 about?
NCT04811365 is a clinical study titled "(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation". This is a multi-center screening study with the primary objective to determine the prevalence of KIT D816V mutation in peripheral blood in patients with evidence of systemic mast cell activation (MCA).
What is the current status of trial NCT04811365?
This trial is currently completed. The enrollment target is 379 participants. The study started on 2021-06-29. Estimated completion is 2023-03-31.
What conditions does trial NCT04811365 study?
This clinical trial studies the following conditions: KIT D816V Mutation, Systemic Mast Cell Activation.
What interventions are being tested in trial NCT04811365?
The interventions under investigation include: Screening (OTHER).
Who is sponsoring clinical trial NCT04811365?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04811365 being conducted?
This trial has 20 study locations across Alabama, California, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for KIT D816V Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI